ClinicalTrials.gg
RecruitingNCT05830344Updated Aug 14, 2023

Effects of Multi Radiance Medical® Super Pulsed Laser on Chronic Knee Pain

An interventional study of Placebo Multi Radiance Medical® Super Pulsed Laser and Active Multi Radiance Medical® Super Pulsed Laser in Knee Pain Chronic, sponsored by University of Nove de Julho. Recruiting at 2 sites in Brazil. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Chronic Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Chronic Pain · Brazil.

Planned enrollment
19th of 61
86 · median 60
Started
2023
with 7 others
No phase
48 of 67
8 open now
Primary completion
2023-10
later than 0 of 11 live
Registered
51st of 67
by date
Lead sponsor
3 of 67
University of Nove de Julho

Among the 67 studies in Chronic Pain with a site in Brazil, this one is the 19th largest by planned enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2023, is one of 48 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 51st registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

10 of the 67 studies in Chronic Pain with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Chronic Pain with a site in Brazil, or all of them as a file.
02

Study summary

Knee pain is among the most common reasons for musculoskeletal pain consultations, accounting for nearly 4 million primary care visits annually. Knee pain can have different causes such as, tendinopathies, synovitis, bursitis, trauma, etc.

Considering the importance and high incidence of musculoskeletal disorders that affect the knee joint, a variety of therapeutic modalities has been employed to alleviate pain and repair the tissue. Among these conservative treatments, photobiomodulation therapy (PBMT) has been shown to stimulate tendon and ligament healing, and decrease the pain.

Therefore, the aim of this study is to determine the effectiveness of the Multi Radiance Medical® Super Pulsed Laser, manufactured by Multi Radiance Medical®, for adjunctive use in providing temporary relief of chronic knee pain of musculoskeletal origin.

Read the detailed description

To achieve the proposed objectives it will be performed a randomized, triple-blind (patients, therapists, outcome assessors), placebo-controlled trial, with voluntary patients with chronic knee pain. Eighty-six patients will be randomly allocated to two treatment groups: 1. Active Multi Radiance Medical® Super Pulsed Laser or Placebo Multi Radiance Medical® Super Pulsed Laser. The patients will be treated by a blinded therapist.

Treatment administration will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments (each treatment administration one to two days apart).

The outcomes will be obtained at the stabilization phase, baseline (pre-procedure), end of treatment and one week after the conclusion of treatment.

The data will be collected by a blinded assessor. The statistical analysis will follow the intention-to-treat principles.

The project was also approved by the Research Ethics Committee from Universidade Nove de Julho, under the number 5.332.202. Board Affiliation: Comissão Nacional de Ética em Pesquisa (CONEP) Phone: +55113385-9010 - Email: comitedeetica@uninove.br Address: Vergueiro nº 235/249. Liberdade, Sao Paulo, Sao Paulo, Brazil.

The investigators will analyze: degree of pain, levels of prostaglandin E2, subjective knee evaluation, patient satisfaction, blinded efficacy and adverse events.

03

Conditions studied

  • Knee Pain Chronic

Browse trials for

Keywords

  • Photobiomodulation Therapy
  • LLLT
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed consent form.
  • Aged between 18 and 50 years, inclusive.
  • Any gender.
  • Subject is fluent in Portuguese.
  • The volunteers' presenting primary (dominant) pain is in the region of the right or left knee only. i.e., it is unilateral.
  • Self-reported degree of pain rating on the 0-100 VAS pain scale for the target knee is 50 or greater.
  • Self-reported degree of pain rating on the 0-100 VAS pain scale for the non-target knee is less than 20.
  • Knee pain is episodic chronic, defined as having occurred and recurred over regular or irregular periods or intervals of time, persisting over at least the last 3 months.
  • Volunteers' knee pain is of benign musculoskeletal origin wherein the etiology is tendinopathies, synovitis, bursitis, strain, and sprain, of traumatic or non-traumatic origin, as determined by the principal investigator based on any one or combination of the following:
  • Prior diagnosis by a qualified licensed medical professional current within the last 2 years evidenced through source documentation.
  • Previous Records Review, such as x-ray, MRI, CT scans, etc., where available, that indicate muscle or ligament injury and the absence of Degenerative Joint Disorder (DJD).
  • Medical history consistent with one of the etiologies of knee pain falling within the scope of this study.
  • Physical examination of the knee that yields one or both of the following findings: Increased pain upon range of motion and/or increased pain and weakness upon knee extension, knee flexion, or gait.
  • Subject is willing and able to maintain his or her individualized pain regimen as determined by the study principal investigator at baseline as needed to manage any knee pain that may arise throughout the course of study duration, whilst refraining from consuming other over the counter and/or prescription medication(s) and/or herbal supplements intended for the relief of pain and/or inflammation, and/or partaking in other treatments/therapies.

Exclusion criteria

Exclusion Criteria:

A volunteer who satisfies any one or more of the following criteria will be excluded from study participation:

  • The volunteers' presenting primary pain is located outside or in addition to the knee.
  • The volunteers' presenting primary pain is bilateral, i.e., equally dominant in the right and left knees.
  • Self-reported degree of pain rating on the 0-100 VAS pain scale for the target knee is less than 50.
  • Self-reported degree of pain rating on the 0-100 VAS pain scale for the non-target knee is 20 or greater.
  • Knee pain is acute, defined as having persisted less than half the time over less than the last 3 months.
  • Knee pain is not episodic, such that it has either been continually present without respite over the past 3 months and/or there has not been recurrent episodes within the past 3 months.
  • Volunteers' knee pain is of other than, or in addition to, benign musculoskeletal origin wherein the etiology is tendinopathies, synovitis, bursitis, strains, and sprains from traumatic or non-traumatic origin, and/or the etiology of the subject's knee pain cannot be satisfactorily ruled out.
  • Prior surgical intervention to the target knee that in the opinion of the principal investigator may affect the study treatment and or outcomes assessment.
  • Neurologic deficits that in the opinion of the principal investigator may affect the study treatment and or outcomes assessment.
  • Peripheral nerve disease.
  • Rheumatoid arthritis.
  • Hip or ankle disease.
  • Congenital or acquired bony deformity in the ipsilateral lower extremity.
  • Secondary orthopedic problems that in the opinion of the principal investigator may affect the study treatment and or outcomes assessment.
  • Local and/or botulinum toxin (Botox®) injection for knee pain relief within 30 days prior to study enrollment.
  • Treatments such as chiropractic care, and acupuncture within 30 days prior to study enrollment.
  • Current, active chronic pain disease, such as chronic fatigue syndrome, fibromyalgia, endometriosis, inflammatory bowel disease, interstitial cystitis diabetic neuropathic pain,
  • Current cancer or treatment for cancer in the past 6 months.
  • Significant heart conditions including chronic heart failure (CHF) and implantable heart devices such as a pacemaker.
  • Active infection, wound, or other external trauma to the areas to be treated with the PBMT.
  • Medical, physical, or other for, or sensitivity to, light therapy.
  • Pregnant, breast feeding, or planning pregnancy prior to the end of study participation.
  • Female subject of childbearing age who is unwilling to engage in effective medical use while sexually active during the study procedure administration phase.
  • Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years.
  • Developmental disability or cognitive impairment that in the opinion of the principal investigator would preclude adequate comprehension of the form and/or ability to record the necessary study measurements.
  • Any other medical condition or medication use that in the opinion of the principal investigator may affect the study treatment and or outcomes assessment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, without any emission of therapeutic dose. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).

    Device: Placebo Multi Radiance Medical® Super Pulsed Laser

  • Experimental
    Active

    Active treatment will be irradiated using a Multi Radiance Medical Super Pulsed Laser, manufactured by Multi Radiance Medical® (Solon,Ohio, USA), at 5 sites in the knee area, with a dose of 8.02 J per site. The treatment will be performed 3 times a week, for four consecutive weeks, yielding 12 treatments.

    Device: Active Multi Radiance Medical® Super Pulsed Laser

Interventions

  • DevicePlacebo Multi Radiance Medical® Super Pulsed Laser

    Placebo, without therapeutic dose.

  • DeviceActive Multi Radiance Medical® Super Pulsed Laser

    Active with a dose of 8.02 J per site.

06

What researchers measure

Primary outcomes

  1. Degree of pain rating

    Degree of pain rating will be measured by 0-100 standardized Visual Analog Scale (VAS). Higher scores mean worse outcome.

    Time frame: 4 weeks (end of treatment).

Secondary outcomes

  1. Degree of pain rating

    Degree of pain rating will be measured by 0-100 standardized Visual Analog Scale (VAS). Higher scores mean worse outcome.

    Time frame: One-week after the conclusion of the treatment.

  2. Levels of Prostaglandin E2 (PGE2)

    Levels of PGE2 will be measured by blood samples.

    Time frame: 4 weeks (end of treatment) and one-week after the conclusion of the treatment.

  3. Subjective knee evaluation

    Subjective knee evaluation will be measured by the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form consisting in 18 items and contains the following three domains: 1) symptoms, including pain, stiffness, swelling, locking/catching, and giving way; 2) sports and daily activities; and 3) current knee function and knee function prior to knee injury (not included in the total score). Scores range from 0 points (lowest level of function and highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).

    Time frame: 4 weeks (end of treatment) and one-week after the conclusion of the treatment.

  4. Patient satisfaction

    Patient satisfaction will be measured by 1-item Likert Scale. The scale uses the following responses: very satisfied = 5; somewhat satisfied = 4; neither satisfied nor dissatisfied = 3; somewhat dissatisfied n=2; very dissatisfied =1. Highest scores indicates better satisfaction.

    Time frame: 4 weeks (end of treatment) and one-week after the conclusion of the treatment.

  5. Blinding efficacy

    The blinding efficacy will be measured by the percentage of volunteers and outcome assessor who correctly perceived their procedure group assignment and the percentage of volunteers and outcome assessor who did not correctly perceive their procedure group .

    Time frame: 4 weeks (end of treatment) and one-week after the conclusion of the treatment.

  6. Adverse events

    Adverse events will be measured by report.

    Time frame: 4 weeks (end of treatment) and one-week after the conclusion of the treatment.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The IPD will be available on reasonable request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The data will become available during five years after the study completion.

Access criteria: All IPD that underlie results in a publication will be available on reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2023, 6 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 6 months is below that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
Apr 26, 2023
StartActual
Apr 27, 2023
Primary completionEst.
Oct 2023
CompletionEst.
Dec 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05830344
Collaborators
Multi Radiance Medical
Responsible party
Ernesto Cesar Pinto Leal Junior (Full professor, University of Nove de Julho) — Principal investigator
First posted
Apr 26, 2023
Start date
Apr 27, 2023
Primary completion
Oct 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Aug 14, 2023

Study contacts

Ernesto Leal Junior, PhD
Contact
ernesto.leal.junior@gmail.com
+551133859134

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion